ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BCRX vs JNJ // NET PROFIT MARGIN

BioCryst Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BCRX 4 — JNJ 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCRX VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BCRX JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% 25.50% +59.50 BCRX /roic <GO>
EV/EBITDA & P/E Valuation 6.1x 18.5x -12.40 BCRX /valuation <GO>
Free Cash Flow Yield 15.96% 2.97% +12.99 BCRX /fcf-yield <GO>
Operating Margin — 34.70% — TIE /operating-margins <GO>
Net Profit Margin ACTIVE — 28.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — 6.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 8/9 -2.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 55.8 62.1 -6.30 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple 7.7x 23.0x -15.30 BCRX /forward-pe <GO>
Enterprise Scale & Market Cap $2.18B $662.49B -$660.31B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BCRX REV JNJ REV BCRX GROSS % JNJ GROSS % BCRX FCF JNJ FCF
FY 2025 $0 $94.19B — 67.9% $347.4M $19.70B
FY 2024 $0 $88.82B — 69.1% -$52.0M $19.84B
FY 2023 $0 $85.16B — — -$95.1M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCRX // BETA —
JNJ // BETA 1.08